
Rui Adão

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8235957/publications.pdf Version: 2024-02-01



<u>Ριμ ΔρÃεο</u>

#	Article	IF	CITATIONS
1	Pulmonary Valve Replacement: A New Paradigm with Tissue Engineering. Current Problems in Cardiology, 2023, 48, 101212.	1.1	1
2	Urocortin-2 in Acute Heart Failure: Role as a Marker of Volume Overload and Pulmonary Hypertension. Current Problems in Cardiology, 2022, 47, 100860.	1.1	3
3	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update. Cardiovascular Drugs and Therapy, 2022, , 1.	1.3	5
4	Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension. Biomolecules, 2022, 12, 484.	1.8	11
5	Urocortins as biomarkers in cardiovascular disease. Clinical Science, 2022, 136, 1-14.	1.8	1
6	Scientists on the Spot: Inflammation in atherosclerosis. Cardiovascular Research, 2021, 117, e7-e8.	1.8	2
7	Highlights of American Heart Association Scientific Sessions 2020: a virtual experience. Cardiovascular Research, 2021, 117, e10-e12.	1.8	0
8	Nicotinamide for the treatment of heart failure with preserved ejection fraction. Science Translational Medicine, 2021, 13, .	5.8	109
9	Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. Cardiovascular Research, 2021, 117, 2474-2488.	1.8	20
10	Avalanching nanoparticles bring new light to cardiovascular imaging. Cardiovascular Research, 2021, 117, e60-e63.	1.8	1
11	Scientist on the Spot: Exploring the cause and cure for pulmonary arterial hypertension. Cardiovascular Research, 2021, 117, e82-e83.	1.8	0
12	Mobile cardiology during the COVID-19 outbreak. Cardiovascular Research, 2020, 116, e149-e151.	1.8	7
13	Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. Frontiers in Pediatrics, 2020, 8, 342.	0.9	35
14	Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. European Journal of Pharmacology, 2020, 889, 173658.	1.7	7
15	Inside the heart of COVID-19. Cardiovascular Research, 2020, 116, e59-e61.	1.8	33
16	Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential. Cardiovascular Drugs and Therapy, 2019, 33, 599-613.	1.3	7
17	Highlights from the ERS International Congress 2018: Assembly 13 – Pulmonary Vascular Diseases. ERJ Open Research, 2019, 5, 00202-2018.	1.1	0
18	Neuregulinâ€1 attenuates right ventricular diastolic stiffness in experimental pulmonary hypertension. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 255-265.	0.9	11

Rui Adão

#	Article	lF	CITATIONS
19	<i>Bmpr2</i> Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. Circulation, 2019, 139, 932-948.	1.6	74
20	Update on pathophysiology and preventive strategies of anthracyclineâ€induced cardiotoxicity. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 204-215.	0.9	39
21	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. Cardiovascular Research, 2018, 114, 880-893.	1.8	52
22	Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension. Cardiovascular Research, 2018, 114, 1165-1177.	1.8	19
23	Effects of urocortin-2 on cellular Ca2+ homeostasis in right heart failure induced by pulmonary artery hypertension. , 2018, , .		1
24	Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension. , 2018, , .		0
25	Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. , 2018, , .		0
26	Improvement in left intraventricular pressure gradients after aortic valve replacement in aortic stenosis patients. Experimental Physiology, 2017, 102, 411-421.	0.9	5
27	Distinct right ventricle remodeling in response to pressure overload in the rat. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H85-H95.	1.5	33
28	Pulmonary arterial hypertension: Basic knowledge for clinicians. Archives of Cardiovascular Diseases, 2016, 109, 550-561.	0.7	34
29	Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. Cardiovascular Research, 2016, 109, 44-54.	1.8	33
30	Cardiotoxicity of Cancer Chemotherapy–Recent Developments. , 2016, , 36-83.		1
31	Urocortin 2 in cardiovascular health and disease. Drug Discovery Today, 2015, 20, 906-914.	3.2	25
32	Abstract 20669: Urocortin-2 Improves Right Ventricular Function in Pulmonary Arterial Hypertension. Circulation, 2014, 130, .	1.6	0
33	Cardiotoxicidade associada à terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção. Revista Portuguesa De Cardiologia, 2013, 32, 395-409.	0.2	62
34	Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 395-409.	0.2	30
35	Lead availability in soils from Portugal's Centre Region with special reference to bioaccessibility. Environmental Geochemistry and Health, 2012, 34, 213-227.	1.8	13
36	An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	8